Aurum Biosciences is a clinical stage biopharma company developing novel oxygen carriers for use as therapeutics & diagnostics, initially for Acute Ischaemic Stroke & Inflammation Imaging. Follow-on indications include heart disease, cardiac arrest, oncology, spinal cord injury & traumatic brain injury.

Aurum's lead product ABL-101 has undergone significant pre-clinical development and has completed early phase 1 and 2a human studies. ABL-101, which has previously received MHRA clinical trial approval in stroke, is planned for phase 2a trials in stroke and inflammation imaging in 2026.

Aurum has funding from The Wellcome Trust, InnoScot, Tricapital Angel Investors, Infinion Biopharma, Scottish Enterprise and a number of notable international and private investors including clinicians with significant stroke expertise. Aurum will be seeking series A funding in 2026 to progress our planned clinical trials and to progress its work in the clinical product pipeline.